Abstract
In allogeneic marrow transplantation (BMT), donor lymphocytes play a central therapeutic role in both graft-versus-leukemia and immune reconstitution. However, their use is limited by the risk of severe graft-vs-host disease (GvHD). Different strategies have been investigated to obtain all the benefits derived from donor lymphocytes while avoiding the risk of GvHD. In the first pilot study, infusions of donor lymphocytes transduced with the herpes simplex virus thymidine kinase (HSV-tk) suicide resulted in anti-tumor activity in 50% of patients. Acute GvHD could be effectively controlled by ganciclovir-induced elimination of the transduced cells. If these results are confirmed in larger studies, genetic manipulation of donor lymphocytes will increase efficacy and safety of allogeneic marrow transplantation.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Kolb HJ, Schattenberg A, Goldman JM, Hertenstein B, Jacobsen N, Arcese W, Ljungman P, Verdonck L, Neiderwieser D, van Rhee F, Mittermueller J, de Witte T, Holler E. Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. Blood, 1995; 86, 2041–2050
Riddell SR, Watanabe KS, Goodrich JM, Li CR, Agha ME, Greenberg, PD. Restoration of viral immunity in immunodeficient humans by adoptive transfer of T cell clones. Science, 1992; 257, 238–241
Rooney CM, Smith CA, Ng CYC, Loftin S, Li C, Krance RA, Brenner MK, Heslpo EH. Use of gene-modified virus-specific T lymphocytes to control Epstein-Barr-virus related lympho-proliferation. The Lancet, 1995; 345, 9–13
Bordignon C and Bonini C. A clinical protocol for gene transfer into peripheral blood lymphocytes for in vivo immunomodulation of donor anti-tumor immunity in patients affected by recurrent disease after allogeneic bone marrow transplantation. Hum. Gen. Ther. 1995; 2, 813–819
Bonini C, Ferrari G, Verzeletti S, Servida P, Zappone E, Ruggieri L, Ponzoni M, Rossini S, Mavilio F, Traversari C, Bordignon C. HSV-TK gene transfer into donor lymphocytes for control of allogeneic graft-versus-leukemia. Science, 1997; 276, 1719–1724
Bordignon C, Notarangelo LD, Nobili N, Ferrari G, Casorati G, Panina P, Mazzolari E, Maggioni D, Rossi C, Servida P, Ugazio AG, Mavilio F. Gene therapy in peripheral blood lymphocytes and bone marrow for ADA-immunodeficient patients. Science, 1995; 270, 470–475
Blaese R M, Culver W K, Miller AD, Carter C, Fleisher T, Clerici M, Shearer G, Chang L, Chiang Y, Tolstoshev P. T lymphocyte-directed gene therapy for ADA-SCID: initial trial results after 4 years. Science, 1995; 270, 475–480.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2000 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Ciceri, F., Bonini, C., Marktel, S., Bordignon, C. (2000). Suicide Gene Transduced T-Cells for the Regulation of the Graft-Versus-Leukemia Effect. In: Berdel, W.E., et al. Transplantation in Hematology and Oncology. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-59592-9_39
Download citation
DOI: https://doi.org/10.1007/978-3-642-59592-9_39
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-64041-4
Online ISBN: 978-3-642-59592-9
eBook Packages: Springer Book Archive